Sponsor Pipeline

iRegene Therapeutics Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
4
Recruiting
1
Disease Areas
Active Trials by Phase
Phase 2
1
Phase 1/2
2
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07028632 The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease Parkinson Disease (PD) Not Yet Recruiting
Phase 1/2
NCT06167681 The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease Parkinson Disease Recruiting
NCT07102342 This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and… Parkinson Disease Recruiting
Phase 1
NCT06608355 The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset… Early-onset Parkinson's Disease Recruiting
NCT07289477 A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy Multiple System Atrophy - Parkinsonian Subtype (MSA-P) Recruiting
NCT07550374 Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced… Parkinson's Disease (PD) Not Yet Recruiting
Disease Areas
Get alerts when iRegene Therapeutics Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free